KissPeptin-10

Kisspeptin-10 is the shortest bioactive fragment of the kisspeptin (metastin) family, a 10-amino-acid C-terminal sequence derived from the KISS1 gene product that retains full potency at its target receptor despite the parent peptide running to 54 residues. Its mechanism centers on KISS1R (also known as GPR54), a G-protein-coupled receptor expressed on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus; when kisspeptin-10 binds KISS1R it triggers GnRH release, placing the fragment at the very top of the hypothalamic-pituitary-gonadal (HPG) axis, upstream of luteinizing hormone and follicle-stimulating hormone secretion. This gatekeeper position makes it a distinctive research tool for probing the neuroendocrine circuitry that governs puberty onset, gonadotropin pulsatility, and fertility-related signaling, since manipulating a single upstream node lets researchers trace downstream reproductive-axis effects with more precision than working at the pituitary or gonadal level directly.

Molecular Identity and Structural Properties

Kisspeptin-10 corresponds to the C-terminal 10-amino-acid sequence of the KISS1 gene product, specifically residues 45–54 of the 54-residue mature kisspeptin (kisspeptin-54). Its sequence is Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, and the C-terminal amidation is conserved across all naturally occurring kisspeptin fragments including kisspeptin-13, kisspeptin-14, and kisspeptin-54. This amide group is critical for receptor binding; peptides lacking C-terminal amidation show markedly reduced affinity for KISS1R. The molecular formula is C63H83N15O12 and the molecular weight is approximately 1302.5 Da, making it small enough for efficient tissue penetration in preclinical models while remaining large enough to exhibit selectivity against off-target G-protein-coupled receptors.

The fragment's brevity is deceptive. Binding studies have consistently shown that the C-terminal decapeptide captures most of the receptor-binding energy of the full-length kisspeptin-54, with EC50 values in the low nanomolar range at KISS1R. This high potency from a short sequence has made kisspeptin-10 the preferred tool for mechanistic studies because it can be synthesized at high purity more readily than the 54-residue parent and degrades more slowly under experimental conditions due to its compact structure. Lyophilized kisspeptin-10 is stable at -20 °C for extended periods and is typically reconstituted in sterile water, acetic acid solution, or PBS depending on the experimental protocol.

KISS1R Signaling Cascade and HPG Axis Activation

KISS1R is a Gq-coupled receptor, and kisspeptin-10 binding initiates a canonical phospholipase C pathway that generates inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium, which in GnRH neurons depolarizes the membrane and triggers exocytotic GnRH release. The resulting GnRH pulse reaches the anterior pituitary via the portal vasculature, where it stimulates gonadotroph cells to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH in turn drives steroidogenesis in testicular Leydig cells (testosterone synthesis) and ovarian theca cells (androstenedione production), while FSH controls Sertoli cell function and granulosa cell aromatization. Researchers studying any node in this axis — from pulse generation to gonadal steroid output — therefore often anchor their work upstream at the kisspeptin/KISS1R interface.

Because kisspeptin neurons are themselves regulated by estrogen, testosterone, and progesterone through receptor-mediated feedback, kisspeptin-10 is also used as a probe to interrogate how steroid feedback is transduced at the hypothalamic level. Administering kisspeptin-10 in models where steroids are experimentally manipulated (e.g., gonadectomy followed by hormone replacement) allows researchers to dissect whether impaired LH pulsatility originates upstream at the kisspeptin neuron or downstream at the GnRH/pituitary interface.

KNDy Neurons and Pulse Generation Research

Kisspeptin neurons in the arcuate nucleus of the hypothalamus co-express neurokinin B (NKB) and dynorphin — the so-called KNDy (kisspeptin/neurokinin B/dynorphin) neuronal population. These neurons are thought to constitute the intrinsic GnRH pulse generator: NKB acts as an autocrine/paracrine "accelerator" that drives synchronous kisspeptin release, while dynorphin serves as the "brake" that terminates each pulse. Kisspeptin-10 is used in this research context as a selective KISS1R agonist that bypasses the upstream NKB/dynorphin circuitry, allowing researchers to test whether downstream GnRH/LH responses are intact independent of the pulse generator machinery. This approach has been valuable in identifying where dysfunction arises in models of hypothalamic amenorrhea, polycystic ovarian syndrome-related anovulation, and age-related reproductive decline.

Puberty Onset and KISS1R Loss-of-Function Research

The KISS1/KISS1R axis was established as a reproductive gatekeeper when two seminal studies published in 2003 demonstrated that loss-of-function mutations in GPR54 caused normosmic idiopathic hypogonadotropic hypogonadism (nIHH) — arrested puberty without anosmia, distinguishing the phenotype from Kallmann syndrome. Kisspeptin-10 has since been used extensively in animal models to rescue gonadotropin secretion in KISS1R-deficient mice, to characterize minimum receptor occupancy required for pubertal activation, and to map the timing windows in early postnatal development when kisspeptin signaling is necessary for proper reproductive axis maturation.

In rodent models, central or peripheral administration of kisspeptin-10 consistently advances the timing of vaginal opening (an external marker of puberty onset in females) and testosterone rise in males, supporting a direct role for kisspeptin signaling in setting the pubertal clock. These findings have spurred interest in understanding whether environmental disruption of kisspeptin signaling — by endocrine-disrupting compounds that activate estrogen receptors on KNDy neurons — could contribute to trends in altered puberty timing observed in epidemiological studies.

Limbic and Behavioral Research Applications

Beyond reproductive physiology, KISS1R expression has been detected in limbic structures including the amygdala, hippocampus, and bed nucleus of the stria terminalis — brain regions involved in stress responses, fear conditioning, social behavior, and mood regulation. This has opened a secondary line of inquiry into whether kisspeptin-10 influences emotionality independently of its HPG axis effects. Rodent studies have reported that kisspeptin-10 administration alters anxiety-like behavior in elevated plus-maze and open-field paradigms, and that the effects are reversible with KISS1R antagonists such as peptide-234, indicating receptor-mediated action rather than off-target effects.

The relevance of this limbic pathway to potential antidepressant or anxiolytic research remains under investigation. The observation that kisspeptin-10 signaling in limbic nuclei may coordinate reproductive readiness with affective state — essentially gating reproductive behavior based on emotional context — has generated interest in whether kisspeptin system dysregulation could contribute to mood disorders associated with reproductive transitions such as postpartum depression or perimenopausal mood changes. These are active areas of preclinical research that kisspeptin-10 continues to enable.

Comparison with Longer Kisspeptin Variants

Kisspeptin-10 is the shortest fragment with full KISS1R potency. Kisspeptin-13 (residues 42–54) and kisspeptin-14 (residues 41–54) share the same C-terminal core and are pharmacologically similar. Kisspeptin-54 (the full mature peptide) was the first fragment used in human experimental medicine and has a longer plasma half-life due to its larger size presenting more protease cleavage sites paradoxically offering some protection through steric effects. In preclinical settings, kisspeptin-10 is typically preferred because:

- Synthesis is more straightforward and higher purity is achievable - The shorter sequence eliminates N-terminal extensions that have some receptor-subtype selectivity in peripheral tissues - Cost per unit activity is lower, enabling larger-cohort studies - Its pharmacokinetics are more predictable in acute bolus dosing paradigms

For studies requiring sustained activation or subcutaneous implants, longer analogs or slow-release formulations of kisspeptin-10 have been explored. Researchers designing experiments should account for kisspeptin-10's relatively short half-life in biological fluids (measured in minutes due to endopeptidase activity) and plan sampling intervals accordingly.

Metabolic and Non-Reproductive Research Angles

Emerging evidence suggests kisspeptin signaling participates in metabolic homeostasis as well. KISS1R expression has been identified in pancreatic beta cells, liver, and adipose tissue, and kisspeptin-10 administration in rodent models modulates insulin secretion and glucose uptake in some experimental contexts. The precise physiological significance of peripheral kisspeptin signaling remains debated, but it has added a metabolic dimension to kisspeptin-10 research that goes beyond the classic HPG axis framework. Researchers working at the intersection of reproductive and metabolic endocrinology — a field energized by the recognition that GLP-1 agonism influences both — are increasingly including kisspeptin-10 challenges in their experimental designs to explore potential crosstalk.

Additionally, kisspeptin-10's original namesake role in tumor metastasis suppression (KISS1 was initially cloned as a metastasis suppressor gene, hence "metastin") continues to generate a lower-volume but persistent research interest in its anti-metastatic properties in melanoma, breast cancer, and gastric cancer cell lines, where KISS1R-mediated signaling appears to reduce invasive behavior.

Practical Considerations for Research Use

Kisspeptin-10 is typically supplied as a lyophilized white powder. Standard reconstitution uses sterile water at a concentration of 0.5–1.0 mg/mL, with aliquoting prior to storage at -20 °C to minimize freeze-thaw degradation. For in vivo rodent experiments, doses reported in the peer-reviewed literature vary widely — from microgram-range central (ICV) injections to milligram-range peripheral (subcutaneous or intravenous) administration — reflecting the CNS-penetration challenge of peptide delivery and the need to achieve effective hypothalamic concentrations. Researchers should consult the primary literature for the specific model, route of administration, and endpoint of interest before establishing their dosing paradigm.

Purity is particularly important for kisspeptin-10 studies given the receptor's sensitivity. Third-party certificates of analysis reporting ≥95% HPLC purity with corresponding mass spectrometry confirmation of the expected molecular weight (1302.5 Da) provide the minimum quality baseline for mechanistic receptor studies. Some research groups additionally request endotoxin testing when the peptide will be used in in vivo inflammation-sensitive models.

Peptides.so currently tracks 60 supplier listings for Kisspeptin-10, with per-mg pricing ranging from $0.05 to $275, giving researchers a wide spread to weigh cost against purity documentation, certificate depth, and third-party testing claims when sourcing for their specific application.

Potential Research Applications

- HPG axis signaling studies — GnRH pulsatility, LH surge, FSH modulation - KISS1R/GPR54 receptor binding and downstream signaling assays - KNDy neuron pulse generator circuit characterization - Puberty onset and precocious puberty rodent models - Fertility and reproductive endocrinology — gonadotropin secretion rescue in hypogonadal models - Hypothalamic amenorrhea and stress-induced anovulation investigation - Gonadal steroid negative-feedback transduction at the hypothalamic level - Limbic system and emotionality — anxiety-like behavior, antidepressant-related assays - Metabolic endocrinology — insulin secretion, glucose homeostasis interaction studies - KISS1 metastasis suppression — anti-invasive signaling in cancer cell line models

Cited Research

de Roux N et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences. 2003. PubMed PMID: 12944565.

Seminara SB et al. The GPR54 gene as a regulator of puberty. New England Journal of Medicine. 2003;349(17):1614-27. PubMed PMID: 14573733.

Ohtaki T et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411(6837):613-7. PubMed PMID: 11385580.

Dhillo WS et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology and Metabolism. 2005;90(12):6609-15. PubMed PMID: 16174713.

Navarro VM et al. Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the mouse. Journal of Neuroscience. 2009;29(38):11859-66. PubMed PMID: 19776272.

Caraty A et al. Kisspeptin synchronizes preovulatory surges in cyclical ewes and causes ovulation in seasonally acyclic ewes. Endocrinology. 2007;148(11):5258-67. PubMed PMID: 17690172.

Serhatlioglu I et al. The antidepressant-like effects of kisspeptin-10 are reversed by kisspeptin antagonist peptide 234 in male rats. Cellular and Molecular Biology. 2024. PubMed PMID: 39605118.

For laboratory research only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.